AngioDynamics Posts Mixed Q1 2027 Results Amid Leadership Transition
Event summary
- AngioDynamics reported $80.9M in Q1 2027 net sales, up 6.9% YoY, with Med Tech segment growing 13.2% YoY.
- GAAP loss per share was $0.17, improved from $0.26 in the prior-year quarter.
- Eric Honroth appointed as President and CEO, effective November 2, 2026, succeeding Jim Clemmer.
- FDA approved IDE for RELIEF study evaluating NanoKnife IRE for benign prostatic hyperplasia.
- Company reiterated fiscal 2027 guidance, expecting net sales of $336M–$341M.
The big picture
AngioDynamics' Q1 2027 results highlight a strategic focus on Med Tech, driven by strong performance in Auryon and NanoKnife platforms. The leadership transition comes at a critical juncture as the company navigates regulatory approvals and market dynamics in the competitive medical technology sector. The FDA's IDE approval for the RELIEF study could open new revenue streams, but execution risks remain.
What we're watching
- Leadership Transition
- How Eric Honroth's leadership will impact AngioDynamics' strategic direction and execution of growth plans.
- Med Tech Growth
- Whether the 13.2% YoY growth in the Med Tech segment can be sustained amid competitive pressures.
- Regulatory Expansion
- The pace at which the RELIEF study progresses and its potential to expand the NanoKnife IRE platform beyond oncology.